Earnings Call Summary for 908 Devices (Q2 2026)

1Key Financial Results and Metrics

Revenue: $16.1 million, a 23% increase year-over-year from $13 million.

Handheld Product and Service Revenue: $15.5 million, up 24% from $12.5 million in Q2 2025.

Recurring Revenue: Represented 31% of total revenue, amounting to $4.9 million, a 4% increase year-over-year.

Gross Profit: $8.3 million, with a gross margin of 52%, up from 49% in the prior year.

Adjusted EBITDA Loss: Reduced to $1.9 million from $3.9 million year-over-year, marking a 50% improvement.

Net Loss: $11.9 million, down from $12.9 million in Q2 2025.

Cash Position: Ended the quarter with $101.5 million in cash and equivalents, with no debt.

2Strategic Updates and Business Highlights

Acquisition of NIRLAB: Successfully integrated, enhancing the narcotics detection portfolio with a cloud-connected platform.

Product Shipments: 198 devices shipped in Q2, bringing the total installed base to 4,101.

Focus Areas for 2026:

Scaling Proven Platforms: Continued momentum in FTIR products, especially the VipIR device, with significant orders from law enforcement agencies.

Extending Platform Leadership: Growth in gas and vapor detection through XplorIR, with a 70% increase in placements year-over-year.

Strengthening Revenue Durability: Building a predictable revenue stream through connected services and OEM partnerships.

3Forward Guidance and Outlook

Revenue Guidance for 2026: Raised to $68 million to $70 million, reflecting 21% to 25% growth year-over-year.

Handheld Product and Service Revenue Growth: Expected to be 23% to 27%, equating to $65 million to $67 million.

Adjusted Gross Margins: Anticipated to remain in the mid- to high 50% range for the full year.

Adjusted EBITDA Loss: Expected to reduce to the mid-single-digit millions, moving closer to breakeven.

4Bad News, Challenges, or Points of Concern

AVCAD Program Uncertainty: The U.S. military's AVCAD program is delayed, and its contribution is excluded from current guidance, representing a potential revenue upside if resolved favorably.

Lower Margins on New Products: NIRLAB and ProtectIR orders are expected to have lower gross margins, which could temper overall margin expansion.

Service Revenue Decline: Anticipated reduction in mass spec service revenue is impacting overall service gross margins.

5Notable Q&A Insights

Bundling Opportunities: There is an increasing appetite for multi-system orders among law enforcement agencies, leveraging the expanded product portfolio.

NIRLAB Integration: Early engagement with 30 agencies indicates strong interest and potential for cross-selling opportunities, particularly in drug identification.

Recurring Revenue Aspirations: The company aims to increase recurring revenue from the current 30% towards 40% over the medium term, particularly through NIRLAB's subscription model.

ProtectIR Order Details: The $6 million ProtectIR order was anticipated but exceeded initial expectations, contributing positively to the second half of 2026. Overall, 908 Devices demonstrated strong quarterly performance with significant growth in revenue and improved margins, while also navigating challenges related to program delays and product integration. The outlook remains positive with strategic initiatives aimed at enhancing revenue durability and expanding market presence.